Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
N/A
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 784 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Polaryx Therapeutics, Inc. Common Stock
Market Cap
$104.68M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.96M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1167.97%
5Y Avg
-1200.09%
Market Cap
$105.44M
Net Profit Margin
-72.28%
TTM Avg
-110.67%
3Y Avg
-76.27%
5Y Avg
-63.46%
Market Cap
$106.23M
Net Profit Margin
-33.92%
TTM Avg
-11.74%
3Y Avg
-13.15%
5Y Avg
-11.88%
Market Cap
$102.54M
Net Profit Margin
6.49%
TTM Avg
-2.90%
3Y Avg
-6.49%
5Y Avg
0.99%
Market Cap
$102.25M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$107.83M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-1332.08%
Market Cap
$108.01M
Net Profit Margin
31.95%
TTM Avg
15.97%
3Y Avg
7.99%
5Y Avg
5.33%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $104.68M | 0.00% | 0.00% | N/A | N/A |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.96M | 0.00% | 0.00% | -1167.97% | -1200.09% |
| Definitive Healthcare Corp. (DH)vs › | $105.44M | -72.28% | -110.67% | -76.27% | -63.46% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.23M | -33.92% | -11.74% | -13.15% | -11.88% |
| The Joint Corp. (JYNT)vs › | $102.54M | 6.49% | -2.90% | -6.49% | 0.99% |
| OnKure Therapeutics, Inc. (OKUR)vs › | $102.25M | 0.00% | 0.00% | 0.00% | 0.00% |
| Immunic, Inc. (IMUX)vs › | $107.47M | 0.00% | 0.00% | 0.00% | 0.00% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.83M | 0.00% | 0.00% | 0.00% | -1332.08% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $108.01M | 31.95% | 15.97% | 7.99% | 5.33% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $108.22M | -4416.22% | -2208.11% | -1104.06% | -736.04% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
